DR. MICHEL C NUSSENZWEIG, M.D.
Osteopathic Medicine at York Ave, New York, NY
License number
New York 184131-1
Category
Osteopathic Medicine
Type
Clinical & Laboratory Immunology
Address
Address
1230 York Ave, New York, NY 10065
Phone
(212) 327-8067
(212) 327-8370 (Fax)
(212) 327-8370 (Fax)
Personal information
See more information about MICHEL C NUSSENZWEIG at radaris.comName
Address
Phone
15 E 91St St #8B, New York, NY 10128
15 E 91St St APT 8B, New York, NY 10128
New York, NY
15 91St St, New York, NY 10128
15 91St St, New York, NY 10128
Professional information
Michel C Nussenzweig, New York NY
Specialties:
Immunologist
Address:
1230 York Ave, New York, NY 10065
Education:
New York University, School of Medicine - Doctor of Medicine
Massachusetts General Hospital - Fellowship - Infectious Disease (Internal Medicine)
Massachusetts General Hospital - Fellowship - Infectious Disease (Internal Medicine)
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Dr. Michel C Nussenzweig, New York NY - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
THE ROCHEFELLER UNIVERSITY HHMI
1230 York Ave SUITE 220, New York 10065
(212) 327-8067 (Phone), (212) 327-8370 (Fax)
1230 York Ave SUITE 220, New York 10065
(212) 327-8067 (Phone), (212) 327-8370 (Fax)
Certifications:
Internal Medicine, 1985
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
New York University
Graduated: 1982
Massachusetts General Hospital
New York University
Graduated: 1982
Massachusetts General Hospital
Michel Claudio Nussenzweig, New York NY
Specialties:
Internal Medicine, Infectious Disease
Work:
Rockefeller University Hospital
1230 York Ave, New York, NY 10065
1230 York Ave, New York, NY 10065
Education:
New York University (1982)
Michel C Nussenzweig, New York NY
Specialties:
Clinical & Laboratory Immunology, Infectious Disease
Work:
Rockefeller University Hospital
1230 York Ave, New York, NY 10065
1230 York Ave, New York, NY 10065
Education:
New York University (1982)
Enhanced Antigen Delivery And Modulation Of The Immune Response Therefrom
US Patent:
2004025, Dec 23, 2004
Filed:
Mar 12, 2004
Appl. No.:
10/800023
Inventors:
Daniel Hawiger - Branford CT, US
Michel Nussenzweig - New York NY, US
Ralph Steinman - Westport CT, US
Laura Bonifaz - Del Alvaro Obregon, MX
Michel Nussenzweig - New York NY, US
Ralph Steinman - Westport CT, US
Laura Bonifaz - Del Alvaro Obregon, MX
International Classification:
G01N033/53, G01N033/567, A61K039/395, C12N005/08
US Classification:
424/144100, 435/007200, 435/372000
Abstract:
The present invention relates to methods for targeting antigen to antigen presenting cells through specific endocytic receptors, which results in persistent antigen presentation in the context of MHC molecules. Such highly efficient antigen presentation results in robust and long lasting immune responses, in particular cell mediated responses. The invention provides for immune compositions containing antibodies to DEC-205 in combination with the antigen for eliciting either T cell mediated immunity when delivered with a dendritic cell maturation factor, or for inducing tolerance when delivered in the absence of a dendritic cell maturation factor. The compositions described in the present invention are effective as a single dose at low concentrations and show efficacy even with non-replicating subunit vaccines.
Enhanced Antigen Delivery And Modulation Of The Immune Response Therefrom
US Patent:
2002018, Dec 12, 2002
Filed:
Aug 9, 2001
Appl. No.:
09/925284
Inventors:
Daniel Hawiger - New York NY, US
Michel Nussenzweig - New York NY, US
Ralph Steinman - Westport CT, US
Michel Nussenzweig - New York NY, US
Ralph Steinman - Westport CT, US
International Classification:
A61K039/395
US Classification:
424/093700, 424/144100, 424/178100
Abstract:
Methods are provided for the enhanced delivery of an antigen to antigen-presenting cells such as dendritic cells by conjugating an antigen to a molecule targeted to an endocytic receptor on the dendritic cell, such as DEC-205. The molecule targeted to an endocytic receptor may be a natural ligand to the receptor or an antibody thereto. Conjugates may be covalent complexes or single-chain polypeptides. Together with modulation of the maturation of the dendritic cell, an enhanced immune response or tolerizing immune response may be generated to the antigen. In addition, conjugate molecules including single-chain polypeptides are provided which contain at least an endocytic receptor-binding molecule and a preselected antigen.
Anti-Igalpha-Igbeta Antibody For Lymphoma Therapy
US Patent:
2002015, Oct 17, 2002
Filed:
Nov 9, 2001
Appl. No.:
10/038107
Inventors:
Michel Nussenzweig - New York NY, US
Assignee:
THE ROCKEFELLER UNIVERSITY
International Classification:
A61K039/395, C07H021/04, C12P021/02, C12N005/06, C07K016/42
US Classification:
424/131100, 536/023530, 435/320100, 435/326000, 530/387200
Abstract:
The present invention provides a novel therapeutic anti-Ig-Ig antibody that binds to an external membrane domain binding region of the Ig-Ig heterodimer present on the cell surface of B cells. The present invention further contemplates nucleic acid sequences, host cells, and methods of producing the antibody protein. Additionally, pharmaceutical compositions comprising the anti-Ig-Ig antibody or expression vector encoding the antibody are contemplated. Methods of inducing B cell elimination and treating a condition of inappropriate B cell activity also are contemplated.
Antibodies Targeting Hiv Escape Mutants
US Patent:
2014001, Jan 16, 2014
Filed:
Jun 21, 2013
Appl. No.:
13/924469
Inventors:
Anthony P. West - Pasadena CA, US
Michel C. Nussenzweig - New York NY, US
Pamela J. Bjorkman - La Canada CA, US
Michel C. Nussenzweig - New York NY, US
Pamela J. Bjorkman - La Canada CA, US
International Classification:
C07K 16/10
US Classification:
4241331, 5303873, 536 2353, 4353201, 435328
Abstract:
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) broadly neutralizing antibodies having improved potency and breadth for neutralizing a range of HIV strains. Combinations of broadly neutralizing antibodies can also improve potency over a single antibody composition.
Anti-Hiv Antibodies Having Increased Potency And Breadth
US Patent:
2013020, Aug 15, 2013
Filed:
Dec 13, 2012
Appl. No.:
13/714398
Inventors:
CALIFORNIA INSTITUTE OF TECHNOLOGY - , US
THE ROCKEFELLER UNIVERSITY - , US
Michel Nussenzweig - New York NY, US
Johannes Scheid - New York NY, US
THE ROCKEFELLER UNIVERSITY - , US
Michel Nussenzweig - New York NY, US
Johannes Scheid - New York NY, US
Assignee:
THE ROCKEFELLER UNIVERSITY - New York NY
CALIFORNIA INSTITUTE OF TECHNOLOGY - Pasadena CA
CALIFORNIA INSTITUTE OF TECHNOLOGY - Pasadena CA
International Classification:
C07K 16/10
US Classification:
4241331, 5303873, 536 2353, 4353201, 435328
Abstract:
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) antibodies having improved potency and breadth.
Compositions And Methods For Improving Potency And Breadth Of Hiv Antibodies
US Patent:
2012028, Nov 15, 2012
Filed:
Jul 25, 2012
Appl. No.:
13/558312
Inventors:
Ron Diskin - Pasadena CA, US
Pamela J. Bjorkman - La Canada CA, US
Michel Nussenzweig - New York NY, US
Johannes Scheid - New York NY, US
Pamela J. Bjorkman - La Canada CA, US
Michel Nussenzweig - New York NY, US
Johannes Scheid - New York NY, US
International Classification:
C07K 16/10, C12N 15/63, C12P 21/02, A61K 39/42, C12N 1/21, A61P 31/18, C12N 15/13, C12N 5/10
US Classification:
4241331, 5303873, 536 2353, 4353201, 435328, 4352523, 435 696
Abstract:
Embodiments of the present invention are directed to compositions and methods for anti-HIV (anti-CD4 binding site) antibodies having improved potency and breadth.